Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported first-quarter earnings of 16 cents per share, compared to a loss of 7 cents a year ago. This beat the consensus of 10 cents.
The biopharma company reported fourth-quarter sales of $62.47 million, up 24% year over year, almost in line with the consensus of $61.54 million.
The company reported an operating income of $21.85 million compared to a loss of $13.25 million a year ago.
Aurinia reported a net income of $23.34 million, better than the loss of $10.75 million a year ago.
Aurinia CEO Peter Greenleaf noted that the company’s commercial organization is focused on educating rheumatologists about the benefits of initiating the drug LUPKYNIS earlier in the treatment paradigm.
Guidance: Aurinia reaffirms fiscal 2025 revenue guidance of $250 million-$260 million versus the consensus of $257.87 million.
Price Action: Aurinia stock is up 2.29% at $8.18 at the last check On Monday.
Read Next:
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.